Genflow Biosciences Plc (LSE:GENF) has successfully completed a second administration of its proprietary SIRT6-centenarian gene therapy in a clinical trial involving elderly dogs. The treatment was well tolerated, with no safety concerns observed, underscoring the strong safety profile of the company’s gene therapy platform.
This achievement marks an important step in Genflow’s strategy to expand its innovative genetic longevity platform beyond human therapeutics and into the growing global animal health market. The company intends to build on this progress by advancing its animal health initiatives and pursuing strategic partnerships to accelerate commercialization opportunities.
About Genflow Biosciences Plc
Founded in 2020 and headquartered in the UK with R&D operations in Belgium, Genflow Biosciences is a biotechnology company focused on developing gene therapies to slow the aging process. Its lead candidate, GF-1002, uses a centenarian variant of the SIRT6 gene, which has shown promising results in preclinical research. The company aims to promote healthier, longer lives and is also exploring therapeutic applications for chronic liver disease.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply